ClassID:

96227

C07F9/65583 - page 2 - CPC Classification

Classification description:

Compounds containing elements of Groups 5 or 15 of the Periodic System; Phosphorus compounds; Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Recent Application in this class:
#301
20200069681
2020-03-05

CANNABINOID RECEPTOR MODULATORS

#302
20200062790
2020-02-27

Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders

#303
20200048288
2020-02-13

PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS

#304
20200040020
2020-02-06

Processes for preparing oligomers

#305
20200040019
2020-02-06

N-phosphonoxymethyl prodrugs of hydroxyalkyl thiadiazole derivatives

#306
20200017534
2020-01-16

Crystalline forms

#307
20200017494
2020-01-16

S1PR2 antagonists and uses therefor

#308
20200017448
2020-01-16

Cannabinoid receptor modulators

#309
20200010493
2020-01-09

Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2,4-diamine

#310
20200002314
2020-01-02

Benzimidazole derivatives

#311
20190388442
2019-12-26

Acyclic Nucleoside Phosphonate Diesters

#312
20190382376
2019-12-19

Pharmaceutical compounds for treatment of medical disorders

#313
20190382375
2019-12-19

Triazole antimicrobial derivative, pharmaceutical composition and use thereof

#314
20190382370
2019-12-19

Metalloenzyme inhibitor compounds

#315
20190367501
2019-12-05

Prodrugs of Nh-acidic compounds

#316
20190330155
2019-10-31

Kinase inhibitors

#317
20190314392
2019-10-17

(R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS

#318
20190309298
2019-10-10

Antiviral agents

#319
20190300555
2019-10-03

Phosphorus prodrugs of pyrazolo-substituted pyrimidine sGC stimulators

#320
20190292208
2019-09-26

Processes for preparing phosphorodiamidate morpholino oligomers

#321
20190292197
2019-09-26

Prodrugs of 2,4-pyrimidinediamine compounds and their uses

#322
20190284181
2019-09-19

PRODRUGS OF NH-ACIDIC COMPOUNDS

#323
20190284144
2019-09-19

Substituted quinazoline compounds and methods of use thereof

#324
20190276480
2019-09-12

Processes for preparing phosphorodiamidate morpholino oligomers

#325
20190276447
2019-09-12

Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease

#326
20190276440
2019-09-12

Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof

#327
20190276406
2019-09-12

Heterocyclic compounds for the treatment of neurological and psychological disorders

#328
20190270761
2019-09-05

Soluble C5aR antagonists

#329
20190270704
2019-09-05

Phenylpyrrolidinone formyl peptide 2 receptor agonists

#330
20190241552
2019-08-08

Substituted aminothiazoles

#331
20190233447
2019-08-01

Protein proximity assay in formalin fixed paraffin embedded tissue using caged haptens

#332
20190233420
2019-08-01

Hormone receptor modulators for treating metabolic conditions and disorders

#333
20190218551
2019-07-18

Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

#334
20190218365
2019-07-18

Non-halogenated flame retardant hindered amine light stabilizer cross-linkers

#335
20190218243
2019-07-18

Processes for the preparation of sofosbuvir and intermediates thereof

#336
20190218236
2019-07-18

Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry

#337
20190218212
2019-07-18

HETEROARYL COMPOUNDS FOR KINASE INHIBITION

#338
20190216808
2019-07-18

Hepatitis B antiviral agents

#339
20190209590
2019-07-11

Skeletal removal of bisphosphonates

#340
20190198773
2019-06-27

Organic electroluminescence device and compound including nitrogen for organic electroluminescence device

#341
20190185498
2019-06-20

Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders

#342
20190183903
2019-06-20

TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS

#343
20190177305
2019-06-13

Isatin-derived compounds, use of the compounds for the treatment of AIDS and method of treatment using these compounds

#344
20190169609
2019-06-06

Antisense antibacterial compounds and methods

#345
20190169214
2019-06-06

Bisphosphonate quinolone conjugates and uses thereof

#346
20190169187
2019-06-06

S1PR2 antagonists and uses therefor

#347
20190152948
2019-05-23

Sulfone pyridine alkyl amide-substituted heteroaryl compounds

#348
20190152942
2019-05-23

Antiproliferative compounds, and their pharmaceutical compositions and uses

#349
20190152941
2019-05-23

Benzazepine derivative, preparation method, pharmaceutical composition and use thereof

#350
20190144695
2019-05-16

Acylphosphine oxide photoinitiators

#351
20190144477
2019-05-16

Fosaprepitant phosphate intermediate and preparation method therefor

#352
20190144473
2019-05-16

Amino compounds for treatment of complement mediated disorders

#353
20190136065
2019-05-09

Compositions comprising a polymeric dye and a cyclodextrin and uses thereof

#354
20190131535
2019-05-02

Heterocyclic compound and organic light-emitting device including the same

#355
20190128893
2019-05-02

Quinone methide analog signal amplification

#356
20190127405
2019-05-02

Quinone methide analog signal amplification

#357
20190127401
2019-05-02

Charged linkers and their uses for conjugation

#358
20190127400
2019-05-02

Charged linkers and their uses for conjugation

#359
20190127399
2019-05-02

Charged linkers and their uses for conjugation

#360
20190127372
2019-05-02

S1PR2 ANTAGONISTS AND USES THEREFOR

#361
20190125894
2019-05-02

Hydrophilic linkers and ligand-drug conjugates thereof

#362
20190125770
2019-05-02

(R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS

#363
20190119470
2019-04-25

Ultraviolet light stabilizing polymeric filler materials

#364
20190112285
2019-04-18

Aminothiazole derivatives useful as antiviral agents

#365
20190100755
2019-04-04

Oligonucleotides for treating expanded repeat diseases

#366
20190085005
2019-03-21

Phosphonate compounds for treatment of complement mediated disorders

#367
20190084937
2019-03-21

Heterocyclic compounds for the treatment of neurological and psychological disorders

#368
20190062356
2019-02-28

PH responsive fluorescent compound, composition for detecting mitophagy using same, and method for detecting mitophagy within cells

#369
20190048033
2019-02-14

Ether compounds for treatment of complement mediated disorders

#370
20190031694
2019-01-31

Electrochromic compound, electrochromic composition, and display element

#371
20190031692
2019-01-31

Compounds for treatment of complement mediated disorders

#372
20190031648
2019-01-31

Prodrugs of NH-acidic compounds

#373
20190031629
2019-01-31

Luminogenic and fluorogenic compounds and methods to detect molecules or conditions

#374
20190023729
2019-01-24

Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders

#375
20190019959
2019-01-17

Phosphine-based compound and organic electroluminescence device including the same

#376
20190016700
2019-01-17

Metalloenzyme inhibitor compounds

#377
20190010177
2019-01-10

Soluble C5aR antagonists

#378
20190010176
2019-01-10

COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN

#379
20180362485
2018-12-20

N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP l, TLL1 AND/OR TLL2 INHIBITORS

#380
20180360859
2018-12-20

Acyclic nucleoside phosphonate diesters

#381
20180354977
2018-12-13

Process for preparation of fosaprepitant dimeglumine and an intermediate thereof

#382
20180354907
2018-12-13

CANNABINOID RECEPTOR MODULATORS

#383
20180346498
2018-12-06

Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof

#384
20180344716
2018-12-06

NOVEL OXAZOLIDINONE DERIVATIVES

#385
20180339055
2018-11-29

BONE TARGETED THERAPEUTICS AND METHODS OF MAKING AND USING THE SAME

#386
20180319828
2018-11-08

Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor

#387
20180319748
2018-11-08

Kinase inhibitors

#388
20180318425
2018-11-08

Bortezomib conjugates and methods using same

#389
20180312476
2018-11-01

Method for preparing oxazolidinone intermediate

#390
20180299456
2018-10-18

In Situ Chemiluminescent Substrates and Assays

#391
20180298043
2018-10-18

Alkyne Compounds for Treatment of Complement Mediated Disorders

#392
20180291049
2018-10-11

Crystalline Forms of Fosnetupitant

#393
20180291047
2018-10-11

ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS

#394
20180291046
2018-10-11

ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS

#395
20180280386
2018-10-04

CANNABINOID RECEPTOR MODULATORS

#396
20180273560
2018-09-27

Phospholipidation of imidazoquinolines and oxoadenines

#397
20180265503
2018-09-20

Compositions and methods for inhibition of the JAK pathway

#398
20180251482
2018-09-06

Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate

#399
20180244704
2018-08-30

Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate

#400
20180223278
2018-08-09

Functionally-modified oligonucleotides and subunits thereof

#401
20180222932
2018-08-09

Chiral reagents for preparation of substituted phosphorodiamidate morpholino oligomers

#402
20180222931
2018-08-09

STAT6 inhibitors

#403
20180222884
2018-08-09

Metalloenzyme inhibitor compounds

#404
20180207298
2018-07-26

Chelated PSMA inhibitors

#405
20180199575
2018-07-19

SUBSTITUTED OXOTETRAHYDROQUINOLINYLPHOSPHINIC ACID AND PHOSPHINIC ACID AMIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS

#406
20180186821
2018-07-05

Protein proximity assay in formalin fixed paffafin embedded tissue using caged haptens

#407
20180186782
2018-07-05

Amide compounds for treatment of immune and inflammatory disorders

#408
20180186767
2018-07-05

Antiproliferative compounds, and their pharmaceutical compositions and uses

#409
20180179186
2018-06-28

Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders

#410
20180164322
2018-06-14

Ultra bright dimeric or polymeric dyes with spacing linker groups

#411
20180162889
2018-06-14

Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of IL-12, IL-23 and/or IFN alpha responses

#412
20180162848
2018-06-14

Compositions and methods for inhibition of the JAK pathway

#413
20180162816
2018-06-14

Heterocyclic compounds for the treatment of neurological and psychological disorders

#414
20180155374
2018-06-07

Bisphosphonates vinylic monomers and polymers and uses thereof

#415
20180110876
2018-04-26

Hydrophilic linkers and ligand-drug conjugates thereof

#416
20180105514
2018-04-19

Heterocyclic amides useful as protein modulators

#417
20180105512
2018-04-19

Substituted benzimidazolium compounds useful in the treatment of respiratory diseases

#418
20180086752
2018-03-29

Compositions and methods of targeting mutant K-RAS

#419
20180086737
2018-03-29

Indazolones as modulators of tnf signaling

#420
20180072762
2018-03-15

ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS

#421
20180071323
2018-03-15

Acyclic nucleoside phosphonate diesters

#422
20180064829
2018-03-08

FLUORESCENT BISPHOSPHONATE ANALOGS

#423
20180064737
2018-03-08

Acyclic nucleoside phosphonate diesters

#424
20180044581
2018-02-15

Electrochromic compound, electrochromic composition, electrochromic element, and electrochromic dimming element

#425
20180037597
2018-02-08

Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine

#426
20180030076
2018-02-01

Crystalline fosaprepitant dicyclohexylamine salt and its preparation

#427
20180030075
2018-02-01

Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders

#428
20180022767
2018-01-25

Compounds for treatment of complement mediated disorders

#429
20180022766
2018-01-25

Ether compounds for treatment of complement mediated disorders

#430
20180019410
2018-01-18

Heterocyclic compound and organic light-emitting device including the same

#431
20180016232
2018-01-18

Solid supports and phosphoramidite building blocks for oligonucleotide conjugates

#432
20180009786
2018-01-11

Heterocyclic compounds and use thereof

#433
20180002312
2018-01-04

TETRA- AND PENTASUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES

#434
20170369771
2017-12-28

Electrochromic material and transmittance variable panel and display device including the same

#435
20170365794
2017-12-21

Condensed cyclic compound and an organic light-emitting device including the same

#436
20170333414
2017-11-23

NOVEL OXAZOLIDINONE DERIVATIVES

#437
20170329195
2017-11-16

Organic compound, electrochromic compound, and electrochromic element, optical filter, lens unit, imaging device, and window component having same

#438
20170327520
2017-11-16

Conjugated bisphosphonates for the diagnosis and therapy of bone diseases

#439
20170313732
2017-11-02

Annelated phenoxyacetamides

#440
20170304330
2017-10-26

Acyclic nucleoside phosphonate diesters

#441
20170298085
2017-10-19

Carbamate, ester, and ketone compounds for treatment of complement mediated disorders

#442
20170298084
2017-10-19

Amide compounds for treatment of complement mediated disorders

#443
20170283446
2017-10-05

SOLUBLE C5aR ANTAGONISTS

#444
20170275315
2017-09-28

Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate

#445
20170267639
2017-09-21

Process for synthesizing oxidized lactam compounds

#446
20170260219
2017-09-14

Phosphonate compounds for treatment of complement mediated disorders

#447
20170260178
2017-09-14

ANTIBACTERIAL COMPOUNDS

#448
20170260124
2017-09-14

NO- and HS-releasing compounds

#449
20170253594
2017-09-07

Heteroaryl compounds for kinase inhibition

#450
20170253563
2017-09-07

Kinase inhibitors

#451
20170247410
2017-08-31

Antibacterial antisense oligonucleotide and method

#452
20170247391
2017-08-31

Thienopyrimidine and thienopyridine compounds and methods of use thereof

#453
20170247367
2017-08-31

Aminopyrimidine kinase inhibitors

#454
20170226142
2017-08-10

Factor D Inhibitors Useful for Treating Inflammatory Disorders

#455
20170224704
2017-08-10

Tropomyosin-related kinase (Trk) inhibitors

#456
20170218001
2017-08-03

Phosphonate nucleosides useful in the treatment of viral diseases

#457
20170218000
2017-08-03

PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS

#458
20170211134
2017-07-27

Thiol-containing cleave reagents and oxidative wash

#459
20170198287
2017-07-13

Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

#460
20170197962
2017-07-13

Heteroaryl compounds for kinase inhibition

#461
20170189410
2017-07-06

Amino compounds for treatment of complement mediated disorders

#462
20170179407
2017-06-22

Condensed cyclic compound and organic light-emitting device including the same

#463
20170174713
2017-06-22

Tank-binding kinase inhibitor compounds

#464
20170162796
2017-06-08

Organic light emitting device and display device having the same

#465
20170158686
2017-06-08

Substituted pyrimidines for inhibiting Raf kinase activity

#466
20170158683
2017-06-08

Compositions and methods for inhibition of the JAK pathway

#467
20170152274
2017-06-01

Charged linkers and their uses for conjugation

#468
20170148997
2017-05-25

Compound and organic light-emitting device including the same

#469
20170143704
2017-05-25

Cannabinoid receptor modulators

#470
20170137411
2017-05-18

Compositions and methods for inhibition of the JAK pathway

#471
20170129909
2017-05-11

Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide

#472
20170114083
2017-04-27

Compounds and compositions as kinase inhibitors

#473
20170114046
2017-04-27

Benzimidazole derivatives

#474
20170101427
2017-04-13

KLK4 inhibitors

#475
20170096440
2017-04-06

Activators of glucokinase

#476
20170089911
2017-03-30

Quinone methide analog signal amplification

#477
20170072075
2017-03-16

Chelated PSMA inhibitors

#478
20170057993
2017-03-02

Ether compounds for treatment of medical disorders

#479
20170057983
2017-03-02

Phosphonate compounds for treatment of medical disorders

#480
20170057953
2017-03-02

Compositions useful for treating disorders related to kit

#481
20170057933
2017-03-02

Polymerizable resins containing a 1,3,5-hexahydro-1,3,5-triazine moiety, methods of making, and dental compositions containing the same

#482
20170050992
2017-02-23

NOVEL ANNELATED PHENOXYACETAMIDES

#483
20170029452
2017-02-02

Phenanthroline phosphonic acid derivative and preparation method therefor and application thereof

#484
20170029378
2017-02-02

Kinase inhibitor

#485
20170015689
2017-01-19

Pyrimidine derivatives

#486
20170015659
2017-01-19

Prodrugs of NH-acidic compounds

#487
20170014408
2017-01-19

Hepatitis B antiviral agents

#488
20170008919
2017-01-12

Crystalline form of oxazolidinone antibiotics and preparation method, composition and use thereof

#489
20170002033
2017-01-05

Acyclic nucleoside phosphonate diesters

#490
20160376587
2016-12-29

Functionally-modified oligonucleotides and subunits thereof

#491
20160376297
2016-12-29

Phosphorous Derivatives as Kinase Inhibitors

#492
20160362433
2016-12-15

ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS

#493
20160362432
2016-12-15

PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS

#494
20160362398
2016-12-15

Amide compounds for treatment of complement mediated disorders

#495
20160355539
2016-12-08

SELECTIVE SOLVENT FREE PHOSPHORYLATION

#496
20160355533
2016-12-08

Crystalline fosaprepitant dicyclohexylamine salt and its preparation

#497
20160340375
2016-11-24

Kinase inhibitors

#498
20160332984
2016-11-17

Compounds and uses thereof for the modulation of hemoglobin

#499
20160318958
2016-11-03

Urea derivatives useful as kinase inhibitors

#500
20160318869
2016-11-03

Heterocyclic compounds for the treatment of neurological and psychological disorders

#501
20160304496
2016-10-20

INDAZOLONES AS MODULATORS OF TNF SIGNALING

#502
20160297774
2016-10-13

Substituted quinazoline compounds and methods of use thereof

#503
20160289212
2016-10-06

Hepatitis B antiviral agents

#504
20160264549
2016-09-15

Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)

#505
20160263566
2016-09-15

Phosphine ligands for catalytic reactions

#506
20160263133
2016-09-15

Phosphonate derivatives and methods of use thereof in the treatment of Alzheimer's disease

#507
20160246152
2016-08-25

Organic compound, electrochromic element containing the same, optical filter, lens unit, imaging device, and window component

#508
20160244469
2016-08-25

Compounds for inhibiting cell proliferation in EGFR-driven cancers

#509
20160229876
2016-08-11

Therapeutically active compositions and their methods of use

#510
20160215008
2016-07-28

Voriconazole sodium phosphate hydrates and polymorphs thereof

#511
20160214959
2016-07-28

Metalloenzyme inhibitor compounds

#512
20160213776
2016-07-28

Adsorption of immunopotentiators to insoluble metal salts

#513
20160207949
2016-07-21

Cytotoxic agents for conjugation to a cell binding molecule

#514
20160176906
2016-06-23

Chemical Compounds

#515
20160176905
2016-06-23

Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate

#516
20160176830
2016-06-23

Luminogenic and fluorogenic compounds and methods to detect molecules or conditions

#517
20160145279
2016-05-26

STAT6 inhibitors

#518
20160136191
2016-05-19

Prodrugs of 2,4-pyrimidinediamine compounds and their uses

#519
20160111654
2016-04-21

Semiconducting material comprising aza-substituted phosphine oxide matrix and metal salt

#520
20160108072
2016-04-21

Electrochromic compound, electrochromic composition, display element, and dimming element

#521
20160102059
2016-04-14

Kinase inhibitors

#522
20160096805
2016-04-07

Kinase inhibitor

#523
20160095932
2016-04-07

Bone targeted therapeutics and methods of making and using the same

#524
20160090394
2016-03-31

Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor

#525
20160083369
2016-03-24

Heterocyclic compounds and use thereof

#526
20160082008
2016-03-24

ERK inhibitors and uses thereof

#527
20160075727
2016-03-17

Compounds and compositions as kinase inhibitors

#528
20160068513
2016-03-10

Fused pyrimidine compounds and use thereof

#529
20160067268
2016-03-10

Phosphonate compounds

#530
20160058864
2016-03-03

Targeted delivery of anti-fungal agents

#531
20160056392
2016-02-25

Organic electroluminescent element, and lighting device and display device which are provided with same

#532
20160046654
2016-02-18

Prodrugs of bicyclic substituted pyrimidine type PDE-5 inhibitors

#533
20160046581
2016-02-18

Factor XIa inhibitors

#534
20160046579
2016-02-18

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

#535
20160024127
2016-01-28

COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN

#536
20160024012
2016-01-28

Process for synthesizing oxidized lactam compounds

#537
20160016983
2016-01-21

Modified nucleic acid

#538
20160015726
2016-01-21

Acyclic nucleoside phosphonate diesters

#539
20160002205
2016-01-07

Substituted 2-aminopyridine protein kinase inhibitor

#540
20160002176
2016-01-07

ERK inhibitors and uses thereof

#541
20150376214
2015-12-31

Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof

#542
20150368208
2015-12-24

Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors

#543
20150361116
2015-12-17

Water-soluble complexing agents and corresponding lanthanide complexes

#544
20150336994
2015-11-26

Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same

#545
20150336993
2015-11-26

MITOCHONDRIA-TARGETED THERANOSTIC AGENTS

#546
20150336992
2015-11-26

OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS

#547
20150336991
2015-11-26

Glucokinase activator compounds, compositions containing such compounds, and methods of treatment

#548
20150336946
2015-11-26

2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment

#549
20150335667
2015-11-26

Substituted (3S,11AR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11A-hexahydro[1,3]oxazolo[3,2-A]pyrido[1,2-D]pyrazine-8-carboxamides as HIV agents

#550
20150330978
2015-11-19

TARGETED MORPHOLINO LIGANDS AND USES THEREOF

#551
20150329530
2015-11-19

Antibacterial compounds

#552
20150313923
2015-11-05

Phosphate compounds, a process for their preparation and pharmaceutical compositions containing them

#553
20150307534
2015-10-29

Methods of treatment using N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide

#554
20150307515
2015-10-29

Compositions and methods for inhibition of the JAK pathway

#555
20150291638
2015-10-15

Methods for preparing anti-viral nucleotide analogs

#556
20150284416
2015-10-08

Linkers for conjugation of cell-binding molecules

#557
20150274761
2015-10-01

Electrochromic compound, electrochromic composition, and display element

#558
20150274725
2015-10-01

Tropomyosin-related kinase (TRK) inhibitors

#559
20150259332
2015-09-17

Compositions and methods for inhibition of the JAK pathway

#560
20150250896
2015-09-10

Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules

#561
20150243908
2015-08-27

Condensed cyclic compound and organic light-emitting device including the same

#562
20150239922
2015-08-27

Water-soluble O-carbonyl phosphoramidate prodrugs for therapeutic administration

#563
20150239921
2015-08-27

Phosphonate compounds for treatment of complement mediated disorders

#564
20150239920
2015-08-27

Ether compounds for treatment of complement mediated disorders

#565
20150239919
2015-08-27

Carbamate, ester, and ketone compounds for treatment of complement mediated disorders

#566
20150239895
2015-08-27

Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders

#567
20150239894
2015-08-27

Amino compounds for treatment of complement mediated disorders

#568
20150239893
2015-08-27

Amide compounds for treatment of complement mediated disorders

#569
20150239868
2015-08-27

Alkyne compounds for treatment of complement mediated disorders

#570
20150239838
2015-08-27

Compounds for treatment of complement mediated disorders

#571
20150239837
2015-08-27

Factor D inhibitors useful for treating inflammatory disorders

#572
20150225436
2015-08-13

PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS

#573
20150223461
2015-08-13

Herbicidally and fungicidally active 3-heteroaryl-isoxazoline-5-carboxamides and 3-heteroaryl-isoxazoline-5-thioamides

#574
20150218194
2015-08-06

Anti-Viral Compounds

#575
20150202205
2015-07-23

Aminopyrimidine kinase inhibitors

#576
20150190389
2015-07-09

Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder

#577
20150175641
2015-06-25

Phosphoramidic acid prodrugs of 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl] pyridine-3-sulfonamide

#578
20150166585
2015-06-18

Bisphosphonates vinylic monomers and polymers and uses thereof

#579
20150165063
2015-06-18

1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment

#580
20150158895
2015-06-11

Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)

#581
20150148313
2015-05-28

Macrocyclic factor VIIa inhibitors

#582
20150133473
2015-05-14

Ring-substituted N-pyridinyl amides as kinase inhibitors

#583
20150126563
2015-05-07

Small molecule inhibitors of the pleckstrin homology domain and methods for using same

#584
20150119365
2015-04-30

Activators of glucokinase

#585
20150119281
2015-04-30

Phosphine derivatives of fluorescent compounds

#586
20150087509
2015-03-26

Substituted pyrazole-containing compounds and their use as pesticides

#587
20150080340
2015-03-19

Boronic acid conjugates of oligonucleotide analogues

#588
20150073140
2015-03-12

Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

#589
20150065463
2015-03-05

Phosphonate derivatives and methods of use thereof in the treatment of Alzheimer's disease

#590
20150057251
2015-02-26

COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN

#591
20150051174
2015-02-19

Phosphonate compounds

#592
20150044142
2015-02-12

Fluorescent phospholipid ether compounds, compositions, and methods of use

#593
20150037396
2015-02-05

Targeting delivery of anti-fungal agents

#594
20150031648
2015-01-29

Phosphate compounds, a process for their preparation and pharmaceutical compositions containing them

#595
20150018315
2015-01-15

Tetra- and pentasubstituted benzimidazolium compounds

#596
20150018314
2015-01-15

Benzimidazolium compounds

#597
20140364397
2014-12-11

Acyclic nucleoside phosphonate diesters

#598
20140357598
2014-12-04

Prodrugs of 2,4-pyrimidinediamine compounds and their uses

#599
20140350059
2014-11-27

NOVEL OXAZOLIDINONE DERIVATIVES

#600
20140349972
2014-11-27

Substituted pyrimidines